Preventing intrathecal administration of vincristine

Peter J Gilbar,* Christine V Carrington†

Committee of Specialty Practice in Oncology, The Society of Hospital Pharmacists of Australia, Suite 3, 27-33 Raglan Street, South Melbourne, VIC 3205.

Correspondence: peter_gilbar@health.qld.gov.au

1. ABC Television. The 7.30 Report. 2004; 5 May. Hospital mistakes. Available at: www.abc.net.au/7.30/content/2004/s1102214.htm (accessed Sep 2004).
2. Schochet SS, Lampert PW, Earle KM. Neuronal changes induced by intrathecal vincristine sulfate. J Neuropathol Exp Neurol 1968; 27: 645-658.
3. Stefanou A, Dooley M. Simple method to eliminate the risk of inadvertent intrathecal vincristine administration [letter]. J Clin Oncol 2003; 21: 2044-2047.
4. Meggs WJ, Hoffman RS. Fatality resulting from intraventricular vincristine administration. J Toxicol Clin Toxicol 1998; 36: 243-246.
5. Alcaraz A, Rey C, Concha A, Medina A. Intrathecal vincristine: fatal myeloencephalopathy despite cerebrospinal fluid perfusion. J Toxicol Clin Toxicol 2002; 40: 557-561.

Online responses are no longer available. Please refer to our instructions for authors page for more information.